Primary endpoint missed
But a subgroup, biomarker, functional or temporal signal survived.
Independent Development Decision Audit
Before you kill the asset—or fund the next trial—determine what actually failed.
HISTAMOS independently separates program failure from asset, target, population, measurement, safety and execution failure—then determines what value genuinely survives and what evidence is required for the next capital decision.
No introductory meeting is required. Start with a short non-confidential written brief.
A difficult or ambiguous readout
Observed event
Missed endpoint · subgroup signal · safety conflict · CRL/hold · pivotal redesign
↓
Independent questionWhat failed—and what still deserves decision credit?
Failure attributionLocate the broken layerDrug · target · exposure · population · endpoint · measurement · statistics · safety · execution
Surviving valuePreserve only what remains credibleNo forced rescue. No automatic program death.
↓
STOPREPAIRPRUNEREPOSITIONMATURECONDITIONAL
Independent by designWe do not run the next trial and do not earn more if we recommend one.
Our jobDetermine whether to stop, repair, narrow, reposition, wait for evidence, or proceed conditionally.
Commercial boundaryOne fixed-scope fee. No royalties, equity, milestones or mandatory follow-on work.
01 — When to use HISTAMOS
Built for the moment when the next development decision is expensive—and the failure attribution is still uncertain.
The best fit is not a routine operational problem. It is a high-stakes decision where multiple scientific explanations remain plausible and the next trial, agency interaction or portfolio allocation depends on choosing among them.
Efficacy and safety disagree
The program may require a boundary, dose, population or architecture decision—not a blanket verdict.
FDA Type C / EOP2 or EMA Scientific Advice is approaching
Stress-test the scientific decision before the regulatory question is locked.
CRL or clinical hold leaves program value unresolved
Separate remediable evidence, measurement, safety or execution failures from asset failure.
The next pivotal study is costly
Identify what must be true before committing capital to population, endpoint, comparator or estimand changes.
Stop, repair or reposition?
Convert ambiguity into bounded competing paths with explicit decision consequences.
02 — Decision routes
HISTAMOS does not begin by asking how to rescue the program.
It begins by asking whether anything decision-grade remains to rescue. The next route is then selected from the surviving evidence—not from a requirement to continue development.
No credible surviving value
Do not spend more capital to preserve a narrative the evidence does not support.
The claim survives; the decision test failed
Repair the specific evidence, measurement, statistical, safety or execution layer.
A narrower claim survives
Let the unsupported branch die and adjudicate the surviving claim independently.
Value moves to another context
Population, line of therapy, regimen or development setting may need to change.
The missing variable is time
When durability or safety follow-up is the true bottleneck, avoid inventing an unnecessary new trial.
Uncertainty is bounded but not closed
Define the evidence obligation and proceed only if the remaining uncertainty is explicit and manageable.
03 — Two engagements
One decision layer before large execution commitments.
Post-Readout Failure Attribution & Rescue Adjudication
For failed, mixed or strategically ambiguous Phase II/III readouts, clinical holds, CRLs or program-level uncertainty.
- What failed—and what did not
- Surviving value and competing causal worlds
- STOP / REPAIR / PRUNE / REPOSITION / MATURE / CONDITIONAL
- Decisive discriminator and next evidence package
Pre-Agency Decision Audit
For FDA Type C, End-of-Phase-2, EMA Scientific Advice or pivotal-design lock when the scientific question itself needs stress-testing.
- Decision question stress-test
- Population / endpoint / comparator / estimand vulnerabilities
- Alternative interpretations the agency may surface
- Questions that deserve scarce regulatory attention
Written scopeTypically within 1 business day
Decision auditTypically 5–7 business days after approved data intake
FormatExecutive decision card + technical evidence dossier
04 — What you receive
A decision package designed for leadership, development and the next external conversation.
The deliverable is not a dashboard, platform license or transfer of our internal engine. It is a confidential, client-specific decision package built around the asset and the next capital decision.
Executive Decision Card
The observed failure, what it does and does not prove, the surviving value, the recommended route and the explicit decision boundary.
- Failure attribution
- Surviving value
- Primary route and alternatives
Technical Evidence Dossier
An auditable scientific account of clinical, functional, biomarker, imaging, treatment-context and contradictory evidence.
- Source-linked evidence tables
- Competing explanations
- Uncertainty and contradiction analysis
Decision-Critical Evidence Map
The missing observable, measurement, comparator, statistical bridge or follow-up clock that prevents a stronger decision.
- Missing observables
- Decision-critical gaps
- What is not yet proved
Development Decision Blueprint
The smallest credible path from the current evidence to the next value-creating decision.
- Decisive discriminator
- Next evidence package
- Stop / continue / redesign boundary
05 — External decision benchmarks
We want the decision logic tested against outcomes that exist outside HISTAMOS.
Public work is separated by evidence strength. Retrospective cases test structural coverage, temporal backtests restrict analysis to information available before the outcome, and prospective records freeze predictions before the external answer is known.
Could the method recover a later successful rescue route?
Used to find blind spots, not to claim prospective accuracy.
Could the decision be reached from information available before the regulatory outcome?
Reduces hindsight leakage and tests decision structure.
Can HISTAMOS call the decision before the answer exists?
The strongest benchmark as the prospective record grows.
06 — Not the right fit
We should not be the first call for every development problem.
If the problem is already known and purely operational, a specialist CRO, CMC group or regulatory consultancy is usually the better tool.
Pure recruitment delay or site-management problem
Known GMP/facility remediation with no unresolved scientific decision
Straightforward regulatory writing or submission publishing
No surviving scientific or development uncertainty
07 — How the engagement works
Private analysis. Tangible delivery. Clean commercial close.
Written scope
You send a short non-confidential description of the readout, the next decision and the decision date. We return a written scope defining the question, required inputs, deliverables, timing and fixed fee.
Approved data intake
Under agreed confidentiality and data terms, you provide only the approved de-identified datasets, documents and metadata needed for the analysis.
Independent HISTAMOS analysis
We perform the work internally. Our engine, source code, analytical rules and operating system are never deployed into or transferred to the client environment.
Decision package
You receive the executive decision card, technical dossier, evidence map and decision blueprint, followed by written clarification within the agreed delivery window.
Send the readout and the next decision date.
Begin with public information or a short non-confidential brief. No meeting, platform purchase or long-term commitment is required.